Slide 1: When Your Path Is Unclear, We Point the Way
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT August 2026 © 2026 CLEARPOINT NEURO 1
Slide 2: Disclaimer: Forward-Looking Statements
DISCLAIMER FORWARD-LOOKING STATEMENTS costs of doing so; risks inherent in the research, development, and regulatory approval of the Company’s new pipeline products and the Company’s ability to continue funding of such research, development, and regulatory Statements in this presentation and discuss
Slide 3: Our Company
Biologics and Drug Delivery OUR COMPANY We Enable Delivery of Both Drug and Device Therapies by Offering Precise Navigation to the Brain and Spine Our Unique Platform Includes Proven Clinical Products Used by Hospitals and Neurosurgeons, and Drug Development Services Used by BioPharma Partners Neuro
Slide 4: The Future of Neuro Biologics and Drug Delivery is Here Today
Our Company The Future of Neuro Biologics and Drug Delivery is Here Today More than 30 Million people in the U.S. alone Neurological diseases cost Americans nearly are estimated to suffer from $800 Billion annually. To reduce these costs, we must severe and debilitating neurological disorders. impro
Slide 5: The Future of Neuro Biologics and Drug Delivery is Here Today
Our Company The Future of Neuro Biologics and Drug Delivery is Here Today Of those 30 million patients, 2.1 million in the U.S. alone have ClearPoint Neuro has 60+ Active Pharma Partners, with 10+ disorders where a ClearPoint BioPharma Partner has already programs accepted for FDA expedited review.
Slide 6: Our 4-Phase Strategy Positions ClearPoint for Decades of Growth
Our Company Our 4-Phase Strategy Positions ClearPoint for Decades of Growth 2026+ 2026+ 2020 – 2025 ESSENTIAL. 2010 – 2019 4 EVERYWHERE. FAST. 3 FORWARD. BUILD A NEW $10B MARKET ALONGSIDE OUR 60+ FUNDED. 1 DESIGN. 2 FOUNDATION. LEVERAGE OUR EXISTING PORTFOLIO TO PENETRATE BIOPHARMA PARTNERS AND DIVE
Slide 7: The Unique ClearPoint Ecosystem Has Been Years in the Making
Design. Discovery. The Unique ClearPoint Ecosystem Has Been Years in the Making SmartFlow IRRAflow Active Neuro Cannula Fluid Exchange System SmartFrame XG ClearPoint Neuro embraced the unmet need in neuro biologics and drug delivery, and has invested more IRRAflow than $200m over the past 15 years
Slide 8: Our Installed Base Has Grown to More than 175 Active Global Centers
Funded. Foundation. Our Installed Base Has Grown to More than 175 Active Global Centers Over 160 employees worldwide focused exclusively on Neuro Active ClearPoint Installation (Additional Sites in Asia, EMEA, LATAM) © 2026 CLEARPOINT NEURO 8
Slide 9: ~50% of the Top Ranked Neurosurgery Programs use ClearPoint Technology
Funded. Foundation. ~50% of the Top Ranked Neurosurgery Programs use ClearPoint Technology US News & World Report Best Neurology/Neurosurgery Hospitals 2025-2026 are recognized for excelling in the treatment of complex, high-risk neurological specialty cases. - UCSF Medical Center - Advent Health Or
Slide 10: Stress-Tested QMS and Operations
Funded. Foundation. Stress-Tested QMS and Operations ClearPoint Neuro assets available to our partners: HQ & training facility in Solana Beach, CA Advanced Research Laboratory in Torrey Pines, CA We have invested in our Research & Development, R&D and manufacturing facility in Carlsbad, CA Quality,
Slide 11: Growth Continues Today While We Prepare for Commercial Drug Approvals
Funded. Foundation. Growth Continues Today While We Prepare for Commercial Drug Approvals HEADQUARTERS R&D, MANUFACTURING ADVANCED RESEARCH LABORATORIES Solana Beach, CA Carlsbad, CA Torrey Pines, CA $48.0-$52.0 (est) 2025 REVENUE GROSS MARGIN (A) (B) $37.0m 63% IRRAflow ACQUISITION OPERATING ROOM E
Slide 12: Executive Leadership Team
Funded. Foundation. EX EC U TI VE LEAD ERS HI P TEAM Experienced Leadership in Place Proven industry operators with decades of experience in medical devices, biopharmaceuticals, and clinical research. Joe Burnett Danilo D’Alessandro Jeremy Stigall Mazin Sabra Paul Larson, MD Ellisa Cholapranee Presi
Slide 13: Fast. Forward. Our 4-Pillar Growth Strategy
Fast. Forward. Our 4-Pillar Growth Strategy Collective $1.0B Existing Market Opportunity Today $300m+ $125m+ $75m+ $500m+ FAST. Existing Market Existing Market Existing Market Existing Market FORWARD. Our Fast. Forward. 4-Pillar Growth Strategy is to Win 20% of an Existing $1.0B Global Market Opport
Slide 14: Pillar 1: Pre-Commercial Biologics & Drug Delivery
Fast. Forward. Pillar 1: Pre-Commercial Biologics & Drug Delivery Pre-Commercial $300m+ Biologics & Existing Market ClearPoint Neuro currently offers a boutique, neuro-focused CRO complete with Drug Delivery device co-development services, pre-clinical testing capabilities, and validated clinical tr
Slide 15: Pillar 2: Neuro Navigation & Robotics
Fast. Forward. Pillar 2: Neuro Navigation & Robotics Neurosurgery $125m+ Navigation Existing Market ClearPoint will provide unmatched flexibility by having a single pre- & Robotics planning software offering several workflows deployed via either MRI, iCT and eventually, Robotics. This strategy balan
Slide 16: Pillar 3: Laser Therapy & Access
Fast. Forward. Pillar 3: Laser Therapy & Access Laser Ablation $75m+ ClearPoint Prism is a mobile laser therapy system featuring innovative non-cooled Therapy Existing Market applicator technology that simplifies setup, reduces power and potentially ablation & Access time, and enables efficient work
Slide 17: Pillar 4: Neurocritical Management
Fast. Forward. Pillar 4: Neurocritical Management Neurocritical Care $500m+ & Active CSF Existing Market ClearPoint’s recent acquisition of IRRAS expands the portfolio with a unique and Exchange disruptive solution for neurocritical care and intracranial fluid management. IRRAflow enables active irr
Slide 18: Clear and Continued Investment in ClearPoint's 4-Pillar Product Pipeline
Fast. Forward. Clear and Continued Investment in ClearPoint’s 4-Pillar Product Pipeline 2026 2027 2028+ ✓Radiopharma Formulation • GLP Study Capable • Bioanalytic Lab Active ✓MRI/CT Imaging Capable • Pre-clinical Z-Axis Bolt • Pathology Lab Active 1 ✓Cell Culture Capability ✓Radiolabeling Active • P
Slide 19: Our Fast. Forward. 4-Pillar Growth Strategy is to Win 20% of an Existing $1.0B Market
Our Fast. Forward. 4-Pillar Growth Strategy is to Win 20% of an Existing $1.0B Global Market Opportunity, Generate $200m in Annual Revenue, 4 NEUROCRITICAL CARE and to Achieve Cash Breakeven and & ACTIVE CSF EXCHANGE Profitability Along the Way Expand Existing Portfolio Into Multiple New Indications
Slide 20: Essential. Everywhere.
Essential. Everywhere. What Does it Mean to be Essential to the Future of Cell and Gene Therapy? 60+ Active Pharma Partners ESSENTIAL. 25+ Active Clinical Trials EVERYWHERE. 15+ Neuro-Focused Indications 10+ Under Regulatory Expedited Review It starts by being unique. 1 Approved Combination Device E
Slide 21: Our Unique Ecosystem Will Play An Essential Role in Cell and Gene Therapy
Essential. Everywhere. Our Unique Ecosystem Will Play An Essential Role in Cell and Gene Therapy Multiple Biologic Specific Comprehensive Flexible Options for Confirmatory A.I. Derived Patient Therapy and Patient & Co-Labeled Pre-Planning Surgeon Selected Volumetric Dosing Data and Tissue Specific S
Slide 22: ClearPoint Neuro Has 60+ Active Pharma Partners, 25+ Active Clinical Trials
Essential. Everywhere. ClearPoint Neuro Has 60+ Active Pharma Partners, 25+ Active Clinical Trials Indication Preclinical Phase 1/2 Phase 3 Commercialization Parkinson’s Disease Epilepsy Dementias Huntington’s Gliomas Rare Genetic Neuromuscular Stroke …and more than 15 additional programs that are u
Slide 23: 10+ Programs Are Already Under FDA Expedited Review
Essential. Everywhere. 10+ Programs Are Already Under FDA Expedited Review Indication Preclinical Phase 1/2 Phase 3 / Pre-Comm Commercialization Parkinson's (BlueRock) – BRT-DA01 Parkinson's (AskBio) – AB-1005 Parkinson's (Kenai) – RNDP-001 Parkinson's (Aspen) – ANPD001 Parkinson’s – (Undisclosed) P
Slide 24: Building Surgical Experience and Capacity to Prepare for Drug Commercialization
Essential. Everywhere. Building Surgical Experience and Capacity to Prepare for Drug Commercialization Experienced CLPT Navigation Existing CLPT Site and Participant in Navigation Site Active CGT Trial © 2026 CLEARPOINT NEURO 24
Slide 25: Our Essential. Everywhere. Strategy Expands Our Vision into a 5-Pillar Growth Strategy
5 Our Essential. Everywhere. Strategy COMMERCIAL DRUG DELIVERY Expands Our Vision into a 5-Pillar Add Capacity for 5,000 cell & gene therapy procedures Launch Co-Labeled Products with 10+ partners that are Growth Strategy Which already under FDA Expedited Review across 8 Indications Will Include Com
Slide 26: Our 4-Phase Strategy Positions ClearPoint for Decades of Growth
Our Company Our 4-Phase Strategy Positions ClearPoint for Decades of Growth 2026+ 2026+ 2020 – 2025 ESSENTIAL. 2010 – 2019 4 EVERYWHERE. FAST. 3 FORWARD. BUILD A NEW $10B MARKET ALONGSIDE OUR 60+ FUNDED. 1 DESIGN. 2 FOUNDATION. LEVERAGE OUR EXISTING PORTFOLIO TO PENETRATE BIOPHARMA PARTNERS AND DIVE